Summary:
In adults with type 2 diabetes, tirzepatide treatment (15 mg weekly) significantly reduced HbA1c and maintained counterregulatory glucagon response during induced hypoglycemia compared to placebo, though it was associated with delayed cortisol and noradrenaline responses and reduced hypoglycemic symptom scores.
| PICO | Description |
|---|---|
| Population | Adults with type 2 diabetes (N=42) undergoing hypoglycemic clamp procedures in a randomized, double-blind, crossover study. |
| Intervention | Tirzepatide 15 mg administered once weekly for 12 weeks before hypoglycemic clamp testing. |
| Comparison | Placebo administered for 12 weeks in a crossover design, with an 8–10 week wash-out period between treatments. |
| Outcome | Tirzepatide significantly reduced HbA1c (-1.5% vs. +0.5% with placebo). Glucagon, growth hormone, and adrenaline responses were maintained. However, cortisol and noradrenaline responses were delayed, correlating with lower symptom scores at the hypoglycemic nadir (p=0.007). Hypoglycemia awareness was similar across groups. |
Source: Thomas R Pieber, et al. “Counterregulatory response to hypoglycemia during a hypoglycemic clamp in people with type 2 diabetes treated with tirzepatide.” Read article here.
